Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03266770
Other study ID # 04-17-30
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 15, 2021
Est. completion date December 12, 2022

Study information

Verified date January 2024
Source University Hospitals Cleveland Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Traditional ureteral stents are commonly used in renal and ureteral procedures, and their use is associated with many morbidities which can affect patients' quality of life. However, replacement of the distal portion of the stent with a thin material may reduce bladder irritative symptoms and allow the ureterovesical junction to coapt---thereby, reducing urinary reflux. The hypothesis is that the RELIEF stent will offer the same function of traditional ureteral stents with the added benefits of minimizing urinary reflux and reducing irritative bladder symptoms.


Description:

Traditional ureteral stents are commonly used in practice to relieve renal obstruction or as a scaffold to promote healing after endoscopic or open/ laparoscopic surgeries involving the ureter. However, there are many morbidities associated with stent placement either due to bladder irritation or backflow of urine to the kidney. The most commonly reported symptoms include urgency, urinary frequency, dysuria, incontinence, hematuria, suprapubic discomfort, and fever due to urinary tract infections and flank pain, which can occur in up to 80% of stented patients. Sometimes, the symptoms are poorly tolerated and can negatively affect patients' quality of life. Shao et al have studied the relationship between bladder filling and the renal pelvic pressure (RPP) in stented patients, which revealed that RPP increased mildly during bladder filling and increased dramatically during voiding, indicating urinary reflux, and thus encouraging early stent removal. Another study showed that patients with stents whose distal coils cross the midline are at higher risk of post-stenting morbidities. Replacement of the distal portion of the ureteral stent with a thin material may reduce bladder irritative symptoms and allow the ureterovesical junction to coapt, thereby eliminating urinary reflux. The Ureteral Stent Company, LLC (USC) is developing the RELIEF™ Ureteral Stent, a single use, disposable ureteral stent (US) device that will provide the traditional function of allowing the passage of urine from the kidney to the bladder with new design enhancements to improve patient care: - A low-profile tether through the intramural ureter segment, minimizing the potential of urinary reflux - Polymeric solid distal coil that minimizes the potential for coil positioning on the trigone, reducing the potential for associated bladder spasms and pain. It is hypothesized that the RELIEF stent will offer the same function of traditional ureteral stents with the added benefits of minimizing the urinary reflux and reducing irritative bladder symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 12, 2022
Est. primary completion date December 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ureteral stone of 5-25 mm measured on plain abdomen X-ray KUB (Kidney Ureter Bladder) or CT (computed tomography). - Upper or middle third ureteral stricture. Exclusion Criteria: - Patients with distal ureteral obstruction - Patients with urinary reflux - Patients requiring bilateral surgical stone management procedure - Intraoperative exclusion: Based on the urologist's discretion, if trauma has been induced to the distal ureter due to ureteroscopy maneuvers, these patients will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
RELIEF Stent
The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).

Locations

Country Name City State
United States University Hospitals Cleveland Medical Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
University Hospitals Cleveland Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (6)

Chambade D, Thibault F, Niang L, Lakmichi MA, Gattegno B, Thibault P, Traxer O. [Study of the safety of double J ureteric stents]. Prog Urol. 2006 Sep;16(4):445-9. French. — View Citation

Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol. 2004 Mar;14(2):111-5. doi: 10.1097/00042307-200403000-00011. — View Citation

Giannarini G, Keeley FX Jr, Valent F, Manassero F, Mogorovich A, Autorino R, Selli C. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int. 2011 Feb;107(4):648-54. doi: 10.1111/j.1464-410X.2010.09482.x. — View Citation

Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002 Apr;59(4):511-6. doi: 10.1016/s0090-4295(01)01644-2. — View Citation

Krebs A, Deane LA, Borin JF, Edwards RA, Sala LG, Khan F, Abdelshehid C, McDougall EM, Clayman RV. The 'buoy' stent: evaluation of a prototype indwelling ureteric stent in a porcine model. BJU Int. 2009 Jul;104(1):88-92. doi: 10.1111/j.1464-410X.2008.08338.x. Epub 2009 Jan 14. — View Citation

Shao Y, Shen ZJ, Zhuo J, Liu HT, Yu SQ, Xia SJ. The influence of ureteral stent on renal pelvic pressure in vivo. Urol Res. 2009 Aug;37(4):221-5. doi: 10.1007/s00240-009-0199-z. Epub 2009 Jun 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Bladder Irritation Symptoms (e.g. Frequency, Urgency, Nocturia, Urine Leakage...) Associated With the RELIEF Stent. Ureteral Stent Symptoms Questionnaire (USSQ Scale) will be used to evaluate bladder irritation symptoms at 24 hours post op. The USSQ produces a score of 19 to 220 or above where a higher score means more or worse symptoms. 24 hours post op
Primary Change in Loin Pain Scores From Baseline The 1-10 Visual Analog Scale part of the Ureteral Stent Symptoms Questionnaire (USSQ Scale) will be used to evaluate the change of loin pain from baseline. The VAS produces a score of 0 to 10 where a higher score means more or worse symptoms. Baseline, Day 30
Secondary Incidence of RELIEF Stent-Related Adverse Events Assessment of adverse events (incidence, relationship to device, severity) attributed to the RELIEF stent compared to established adverse event rates from published clinical studies and FDA reported events of conventional ureteral stents. 0-30 days.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06110299 - Room Air a Safe Alternative to Dye Injection in Ureterography N/A
Completed NCT01741454 - Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Phase 4
Completed NCT00790686 - Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Phase 2
Completed NCT00568724 - Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis N/A
Completed NCT00250406 - Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Phase 2
Terminated NCT02419339 - Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction
Completed NCT00301470 - Functional MR Urography Phase 4
Enrolling by invitation NCT05022199 - Use of SPY Fluorescent Angiography to Reduce Ureteroenteric Stricture Rate Following Urinary Diversion N/A
Enrolling by invitation NCT02160652 - Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction N/A
Recruiting NCT01788865 - Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Phase 4
Completed NCT02744430 - Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain Phase 2
Completed NCT00169650 - Laparoscopic Pyeloplasty Registry and Database N/A
Completed NCT01542593 - Evaluating Ureteral Length Using Computed Tomography (CT) N/A
Completed NCT00166361 - Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent N/A
Completed NCT00142064 - A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Phase 2
Completed NCT04695951 - Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract Phase 2
Withdrawn NCT00199472 - Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO N/A